BOSTON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, and Blueprint Genetics, a Quest Diagnostics company, today announced the Resonate program. The program offers genetic testing to eligible individuals with auditory neuropathy at no cost to participants, their insurance, or their healthcare providers.
Every year, thousands of children are born with disabling hearing loss and the majority of cases of congenital hearing loss are due to an underlying genetic cause. However, few individuals receive a genetic diagnosis and a key barrier is the availability and accessibility of genetic testing. The Resonate program seeks to overcome the barriers to genetic testing for individuals with auditory neuropathy, empower them to make informed choices, and provide potentially valuable insight to inform medical management.
Akouos is committed to deepening the community's understanding of the genetic forms of auditory neuropathy, a type of sensorineural hearing loss. Today, there are no pharmacologic therapies approved for the treatment of hearing loss. The development of new therapeutic options for underserved patient populations has become increasingly reliant on identification of the underlying genetic cause of a genetic disease, disorder, or condition, said Manny Simons, Ph.D., founder, president, and CEO of Akouos. We hope the Resonate program, along with our efforts to better understand the genetic causes and natural history of multiple forms of sensorineural hearing loss, will enable the research and development of novel genetic medicines for individuals with disabling hearing loss.
There are many different genetic changes that cause hearing loss. These changes can be complex and difficult for routine genetic testing to detect. Understanding the genetic cause of hearing loss requires a high-quality genetic testing strategy that includes the mitochondrial genome, difficult-to-sequence genes, and deep intronic variants in addition to copy number variants in order to increase the diagnostic potential for the program participant. We are excited to work with Akouos to offer our comprehensive genetic testing approach to individuals with auditory neuropathy, says Tero-Pekka Alastalo, M.D., Ph.D., executive medical director of Blueprint Genetics.
The Resonate program is available in the United States and plans to expand to additional geographic regions throughout 2021. To be eligible for the program, individuals can be any age, and must have a current or prior clinical diagnosis of auditory neuropathy, or a medical history consistent with auditory neuropathy. Auditory neuropathy is a hearing disorder in which the inner ear successfully detects sound, but has a problem with sending sound from the ear to the brain.In many cases, genetic mutations cause auditory neuropathy. The Resonate program provides access to the Blueprint Genetics Comprehensive Hearing Loss and Deafness Panel that includes more than 230 genes associated with genetic forms of hearing loss. To help understand their results, participants in the United States also have access to genetic counseling provided by the program at no cost to participants, their insurance, or their healthcare providers.
For more information on the Resonate program, individuals and families please visit http://www.akouosresonate.com and healthcare providers please visit http://www.blueprintgenetics.com/resonate-program.
About AkouosAkouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. http://www.akouos.com
About Blueprint GeneticsBlueprint Genetics, a Quest Diagnostics company, is a leading specialty genetics and bioinformatics company focused on providing genetic testing for inherited diseases. The company is based in Helsinki and Seattle, with a customer base spanning over 70 countries.www.blueprintgenetics.com
Cautionary Note Regarding Akouos Forward-Looking StatementsStatements in this press release about Akouoss future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expectations for the Resonate program and the roll-out of the Resonate program. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Akouoss plans to develop and, if approved, subsequently commercialize Akouoss product candidates; the timing of and Akouoss ability to submit applications for, and obtain and maintain regulatory approvals for, Akouoss product candidates; Akouoss expectations regarding Akouoss regulatory strategy; Akouoss expectations regarding Akouoss ability to fund Akouoss operating expenses and capital expenditure requirements with Akouoss cash, cash equivalents and marketable securities; the potential advantages of Akouoss product candidates; the rate and degree of market acceptance and clinical utility of Akouoss product candidates; Akouoss estimates regarding the potential addressable patient population for Akouoss product candidates; Akouoss commercialization, marketing and manufacturing capabilities and strategy; Akouoss expectations regarding Akouoss ability to obtain and maintain intellectual property protection for Akouoss product candidates; Akouoss intellectual property position; Akouoss ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with Akouoss commercial objectives; the impact of government laws and regulations; Akouoss competitive position and expectations regarding developments and projections relating to Akouoss competitors and any competing therapies that are or become available; developments and expectations regarding developments and projections relating to Akouoss competitors and Akouoss industry; the impact of the COVID-19 pandemic on Akouoss business, results of operations, and financial condition; Akouoss ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the Risk Factors included in Akouoss Quarterly Report on Form 10-Q for the three months ended September 30, 2020 filed with the Securities and Exchange Commission, and in other filings that Akouos makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Akouos expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Akouos
Media:Katie Engleman, 1ABkatie@1abmedia.com
Investors:Courtney Turiano, Stern Investor RelationsCourtney.Turiano@sternir.com
Blueprint Genetics
Tero-Pekka Alastalo, executive medical directortpa@blueprintgenetics.com
Saara Salonoja, communication specialistsaara.salonoja@blueprintgenetics.com
Here is the original post:
Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy -...
- Sequence errors are canaries in a coal mine in genetics studies, sleuth says - Retraction Watch - March 30th, 2025 [March 30th, 2025]
- Significance of noninvasive prenatal testing using massively parallel sequencing in women with twin or vanishing twin pregnancies | Journal of Human... - March 30th, 2025 [March 30th, 2025]
- All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- 23andMe Stock Is Surging After a Bankruptcy Judge Cleared Genetics Business Sale. Heres Why You Need to Stay Far Away From ME Shares. - Barchart - March 30th, 2025 [March 30th, 2025]
- Dairy producers leverage genetics to optimize milk composition for processing - Feedstuffs - March 30th, 2025 [March 30th, 2025]
- Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- Human genetics and biotechnology company 23andMe to pursue bankruptcy sale after failed prepetition attempt Case Profile - ION Analytics - March 30th, 2025 [March 30th, 2025]
- AP Biology Students At NLHS Explore Genetics With Build-A-Baby Monster Lab - EastTexasRadio.com - March 30th, 2025 [March 30th, 2025]
- Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance - March 15th, 2025 [March 15th, 2025]
- Helix Unveils Groundbreaking Real-World Insights at the ACMG Annual Clinical Genetics Meeting, Driving Clinical Care Forward - PR Newswire - March 15th, 2025 [March 15th, 2025]
- S2 Episode 3: Molecular Classification and Genetics of Endometrial Cancer - Medscape - March 15th, 2025 [March 15th, 2025]
- Fowl Play: How Chicken Genetics Barons Created the Egg Crisis - The Big Newsletter - March 15th, 2025 [March 15th, 2025]
- Exposure to violence alters human genetics for future generations - Earth.com - March 5th, 2025 [March 5th, 2025]
- Family-based genetics identifies association of CUBN IL1RL1 and PRKN variants with leprosy in Bangladesh - Nature.com - March 5th, 2025 [March 5th, 2025]
- The role of genetics in infant hearing loss: What parents need to know - The Times of India - March 5th, 2025 [March 5th, 2025]
- Analyzing Genetics May Lead to Better Contraceptive Experiences for Women - Yale School of Medicine - March 5th, 2025 [March 5th, 2025]
- Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance - March 5th, 2025 [March 5th, 2025]
- Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the... - February 25th, 2025 [February 25th, 2025]
- Dual recombinase-mediated intersectional genetics defines the functional heterogeneity of neural stem cells in adult hippocampus - Nature.com - February 25th, 2025 [February 25th, 2025]
- Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - Yahoo Finance - February 25th, 2025 [February 25th, 2025]
- The Genetics of Creativity: Can Creative Talent Be Inherited? - Etownian - February 25th, 2025 [February 25th, 2025]
- Weight and metabolism determined more by genetics than diet - WVTF - February 25th, 2025 [February 25th, 2025]
- Beyond genetics: The biggest factors that influence health and aging - Earth.com - February 25th, 2025 [February 25th, 2025]
- Study finds lifestyle, environment have greater impact on lifespan than genetics - CBS Boston - February 25th, 2025 [February 25th, 2025]
- 6 Things to Know About Genetics in GI Cancers - Gastroenterology & Endoscopy News - February 25th, 2025 [February 25th, 2025]
- Virologist Wendy Barclay: Wild avian viruses are mixing up their genetics all the time. Its like viral sex on steroids - The Guardian - February 3rd, 2025 [February 3rd, 2025]
- Do you find coffee too bitter? Scientists explain how your genetics and roasting process affect the flavour - Hindustan Times - February 3rd, 2025 [February 3rd, 2025]
- 2025 Illinois Performance Tested Bull Sale prioritizes trusted genetics for herd growth - Morning Ag Clips - - February 3rd, 2025 [February 3rd, 2025]
- Game-Changing Cancer Detection Tool Spots What Others Miss: New Breakthrough from SOPHiA GENETICS - StockTitan - February 3rd, 2025 [February 3rd, 2025]
- Integrative genetics and multiomics analysis reveal mechanisms and therapeutic targets in vitiligo highlighting JAK STAT pathway regulation of CTSS -... - January 23rd, 2025 [January 23rd, 2025]
- deCODE genetics: Complete recombination map of the human-genome, a major step in genetics - Financial Times - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - Yahoo Finance - January 23rd, 2025 [January 23rd, 2025]
- Bjarni V. Halldorsson and Kari Stefansson, scientists at deCODE genetics, discuss the paper: Complete recombination map of the human-genome, published... - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan - January 23rd, 2025 [January 23rd, 2025]
- Genetics, brain development, and mental health shape teen eating - News-Medical.Net - January 15th, 2025 [January 15th, 2025]
- Building Better Flu Shots Based on Antibody Responses and Genetics - Vax-Before-Travel - January 15th, 2025 [January 15th, 2025]
- Its in the Genes: Weight and Metabolism Determined by Genetics More Than Diet - Cville Right Now - January 15th, 2025 [January 15th, 2025]
- It's in the genes: Weight and metabolism determined by genetics more than diet - Medical Xpress - January 15th, 2025 [January 15th, 2025]
- Trump and Musk are obsessed with genetics but theres no science behind their simplistic views - The Guardian - January 1st, 2025 [January 1st, 2025]
- From Stonehenge's origins to ice age baby genetics how well did you follow this year's top archaeology stories? - Livescience.com - January 1st, 2025 [January 1st, 2025]
- William Thilly, MIT genetics professor who invented Apple Jacks cereal, dies at 79 - The Boston Globe - January 1st, 2025 [January 1st, 2025]
- Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- With 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD - Neurology Live - December 23rd, 2024 [December 23rd, 2024]
- Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan - December 23rd, 2024 [December 23rd, 2024]
- Redecan Cannabis Launches New Limited-Edition Genetics and Expands Signature 'Wrapped & Redee' Pre-roll Line for the Holidays - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Surprising yields, impressive genetics and an early harvest in 2024 Ohio Ag Net - Ohio's Country Journal and Ohio Ag Net - December 9th, 2024 [December 9th, 2024]
- Using music to help people with dementia; supporting breastfeeding radiologists; genetics and Type 2 diabetes; plus other news stories with VUMC... - December 9th, 2024 [December 9th, 2024]
- Genetics and suicideWhats the link? - Genetic Literacy Project - December 9th, 2024 [December 9th, 2024]
- Genetics is all fun and games for a Rochester card game creator - Rochester Post Bulletin - November 28th, 2024 [November 28th, 2024]
- Community engagement conduct for genetics and genomics research: a qualitative study of the experiences and perspectives of key stakeholders in Uganda... - November 28th, 2024 [November 28th, 2024]
- Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics - Nature.com - November 28th, 2024 [November 28th, 2024]
- Texas A&M Researchers Uncover Secrets Of Horse Genetics For Conservation, Breeding - Texas A&M University Today - November 20th, 2024 [November 20th, 2024]
- Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire - November 20th, 2024 [November 20th, 2024]
- Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance - November 20th, 2024 [November 20th, 2024]
- Precision mutational scanning: your multipass to the future of genetics - Nature.com - November 20th, 2024 [November 20th, 2024]
- Advancements of Haploid Technology in Crops: New Horizons in Breeding and Genetics - Frontiers - November 20th, 2024 [November 20th, 2024]
- Toward advances in retinoblastoma genetics in Kenya - Nature.com - November 12th, 2024 [November 12th, 2024]
- CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production - Nature.com - November 12th, 2024 [November 12th, 2024]
- Genetics Play Key Role in Animal Health and Welfare, Aggression and Handling - Farms.com - November 12th, 2024 [November 12th, 2024]
- Episode 174: Rudy Tanzi talks about genetics, aging and the hallmarks of Alzheimers - IHMC - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Pharmaceutical Technology - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - WV News - October 26th, 2024 [October 26th, 2024]
- Faculty of Science | Protecting Canadas number one crop through genetics - UM Today - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance - October 26th, 2024 [October 26th, 2024]
- Opinion | Fascinated by genetics? Where are the peas Trump made to fornicate? - The Washington Post - October 13th, 2024 [October 13th, 2024]
- Dietary restriction can extend lifespan but genetics matters more - Nature.com - October 13th, 2024 [October 13th, 2024]
- 'They have much stronger players' - Bangladesh assistant coach bizarrely blames 'genetics' for lack of six hitters in the team - Sporting News - October 13th, 2024 [October 13th, 2024]
- Medical Moment: Genetics and breast cancer with USA Health Genetic Counselor Cassie Gurganus - AOL - October 13th, 2024 [October 13th, 2024]
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer - Yahoo Finance - October 13th, 2024 [October 13th, 2024]
- An ideologically-based and misleading critique of how modern genetics is taught - Why Evolution Is True - October 13th, 2024 [October 13th, 2024]
- 2024 Mercedes-AMG C63 Review: Bold But Beholden to Its Genetics - Newsweek - October 2nd, 2024 [October 2nd, 2024]
- Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date - GlobeNewswire - October 2nd, 2024 [October 2nd, 2024]
- Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care... - October 2nd, 2024 [October 2nd, 2024]
- The role of genetics in depression | Second Opinion - KCRW - September 23rd, 2024 [September 23rd, 2024]
- Tilapia genetics company Spring Genetics teams up with UK data firm to improve fish welfare - SeafoodSource - September 23rd, 2024 [September 23rd, 2024]
- Picky eating in kids is mostly due to genetics, study says - Motherly Inc. - September 23rd, 2024 [September 23rd, 2024]
- Research Shows That Fussy Eating In Children Is Mainly Influenced By Genetics - RTTNews - September 23rd, 2024 [September 23rd, 2024]
- Genetics colloquium: Chris Hittinger on the genomic making of metabolic niche breadth Sep. 11 - University of WisconsinMadison - September 15th, 2024 [September 15th, 2024]